Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

England Rejects Funding For Kimmtrak, Onureg & Minjuvi But Says Yes To Idefirix, Evrenzo & Verzenios

Executive Summary

Immunocore’s advanced uveal melanoma drug, Kimmtrak, and Hansa’s Idefirix for increasing the chances of a successful kidney transplant are among the latest treatments that NICE has appraised regarding their cost-effectiveness.

You may also be interested in...



Keytruda: NICE Rejects English Funding For Endometrial Cancer But Says Yes For Renal Cancer

NICE has preliminarily rejected MSD’s drug for endometrial cancer in a decision that contrasts with that of its health technology assessment counterpart in Scotland.

Improved Discount Helps Lilly Secure English Funding For Verzenios

Verzenios is now the second CDK4/6 inhibitor for advanced breast cancer that can be used routinely on England’s National Health Service in patients in a second-line setting.

EPO Supports Early Unitary Patent Uptake From 1 January

The European Patent Office has adjusted the starting date of its transitional measures for applicants that want their patent to have unitary effect under the coming Unified Patent Court system.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS146382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel